Unique ID issued by UMIN | UMIN000011667 |
---|---|
Receipt number | R000013638 |
Scientific Title | Prevention of postoperative VTE using Enoxaparin in laparoscopic gastrectomy and colectomy for malignancies. |
Date of disclosure of the study information | 2013/10/01 |
Last modified on | 2018/09/10 19:47:06 |
Prevention of postoperative VTE using Enoxaparin in laparoscopic gastrectomy and colectomy for malignancies.
Prevention of postoperative VTE using Enoxaparin in laparoscopic gastrectomy and colectomy for malignancies.
Prevention of postoperative VTE using Enoxaparin in laparoscopic gastrectomy and colectomy for malignancies.
Prevention of postoperative VTE using Enoxaparin in laparoscopic gastrectomy and colectomy for malignancies.
Japan |
Gastric and colon cancer
Surgery in general | Gastrointestinal surgery |
Malignancy
NO
To evaluate the preventing efficacy of postoperative VTE using Enoxaparin in laparoscopic gastrectomy and colectomy for malignancies.
Safety,Efficacy
Incidence of VTE.
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
No treatment
2
Prevention
Medicine |
Administration of Enoxaparin(2000IU twice a day, POD1-7) and mechanical thromboprophylaxis(POD1)
mechanical thromboprophylaxis(POD1)
40 | years-old | <= |
Not applicable |
Male and Female
Postoperative function of the major organs(bone marrow, liver, kidneys, etc.) are held sufficiently; patients that meet the following criteria (hemoglobin : 9.5g/dl or more, ALT and AST: 2.5 times less than the normal value of the facility, total bilirubin: 3.0mg/dl or less, SpO2: 90% or more).
1)Patients with heparin-induced thrombocytopenia or patients with a history of hypersensitivity of to heparin or related substances(HIT).
2)Patients with acute bacterial endocarditis
3)Patients with severe to moderate renal dysfunction(creatinine clearance below 50mL/min).
4)Patients with severe liver failure.
5)Low-weight patients (weight less than 40kg)
6)Women who may possibly be pregnant or are pregnant.
7)Patients receiving antiplatelet drugs (such as clopidogrel or aspirin) or anticoagulant drugs (warfarin etc.)
affecting hemostasis preoperatively.
8)Patients with venous thromboembolic disease was observed within one year prior to surgery of this study or the patient with clinical signs or merger of deep vein thrombosis.
9)Ppatients with contraindications of
iodinated contrast agent.
10)Patients who have indwelling central venous catheter.
11)Patients treated with progesterone and estrogen formulation within 4 weeks before administration.
12)Patients receiving radiation therapy or systemic cancer chemotherapy within two weeks before the administration.
13)Patients is determined inappropriate as a test target by principal investigator.
450
1st name | |
Middle name | |
Last name | Akinobu Taketomi |
Hokkaido Univ. Graduated School of Medicine
Gastroenterological Surgery 1
N15, W-7, Kita-ku Sapporo, Hokkaido
011-706-5927
taketomi@med.hokudai.ac.jp
1st name | |
Middle name | |
Last name | Hirofumi Kamachi |
Hokkaido Univ. Graduated School of Medicine
Gastroenterological Surgery 1
N15, W-7, Kita-ku Sapporo, Hokkaido
011-706-5927
hkamachi@db3.so-net.ne.jp
Gastroenterological Surgery 1
Hokkaido Univ. Graduated School of Medicine
Gastroenterological Surgery 1
Hokkaido Univ. Graduated School of Medicine
Self funding
NO
2013 | Year | 10 | Month | 01 | Day |
Unpublished
Completed
2013 | Year | 08 | Month | 08 | Day |
2013 | Year | 12 | Month | 09 | Day |
2017 | Year | 10 | Month | 01 | Day |
2013 | Year | 09 | Month | 06 | Day |
2018 | Year | 09 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013638